Drug Trial Radar · NCT00589693
To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia
Last checked: Nov 20, 2026Latest source record: Dec 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
274
Actual
Start
Apr 2008
Primary completion
Jun 2011
Study completion Jun 2011
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 10, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.
Conditions
- Ventilator-Associated Pneumonia
Interventions
DoripenemDrug
Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
Imipenem-CilastatinDrug
Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
PlaceboDrug
Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Cure Rate at the End-of-treatment (EOT) VisitTime frame: End-of-treatment (Day 10 or Day 11)
Locations
100 sites in 21 countries. Site status is shown where the registry gives one.
Site not named
Jonesboro, Arkansas
Site not named
Newark, Delaware
Site not named
Washington D.C., District of Columbia
Site not named
Jacksonville, Florida
Site not named
Moline, Illinois
Site not named
Hazard, Kentucky
Site not named
Biddeford, Maine
Site not named
Baltimore, Maryland
Site not named
Detroit, Michigan
Site not named
Butte, Montana
Site not named
Buffalo, New York
Site not named
Winston-Salem, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Site not named
Milwaukee, Wisconsin
Site not named
Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Entre Ríos, Argentina
Site not named
Monte Grande, Argentina
Site not named
Rio Negro, Argentina
Site not named
Rosario, Argentina
Site not named
Adelaide, Australia
Site not named
Box Hill, Australia
Site not named
Clayton, Australia
Site not named
Melbourne, Australia
Site not named
Parkville, Australia
Site not named
Brussels, Belgium
Site not named
Ghent, Belgium
Site not named
Belo Horizonte, Brazil
Site not named
Curitiba, Brazil
Site not named
Fortaleza, Brazil
Site not named
Porto Alegre, Brazil
Site not named
Rio de Janeiro, Brazil
Site not named
Santo André, Brazil
Site not named
São José do Rio Preto, Brazil
Site not named
São Paulo, Brazil
Site not named
Halifax, Nova Scotia, Canada
Site not named
Ottawa, Ontario, Canada
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.